Literature DB >> 18467078

Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics.

Dorien Groenendaal1, Jan Freijer, Andrea Rosier, Dennis de Mik, Glynis Nicholls, Anne Hersey, Andrew D Ayrton, Meindert Danhof, Elizabeth C M de Lange.   

Abstract

The objective of this investigation is to characterize the role of complex biophase distribution kinetics in the pharmacokinetic-pharmacodynamic correlation of a wide range of opioids. Following intravenous infusion of morphine, alfentanil, fentanyl, sufentanil, butorphanol and nalbuphine the time course of the EEG effect was determined in conjunction with blood concentrations. Different biophase distribution models were tested for their ability to describe hysteresis between blood concentration and effect. In addition, membrane transport characteristics of the opioids were investigated in vitro, using MDCK:MDR1 cells and in silico with QSAR analysis. For morphine, hysteresis was best described by an extended-catenary biophase distribution model with different values for k1e and keo of 0.038+/-0.003 and 0.043+/-0.003 min(-1), respectively. For the other opioids hysteresis was best described by a one-compartment biophase distribution model with identical values for k1e and keo. Between the different opioids, the values of k1e ranged from 0.04 to 0.47 min(-1). The correlation between concentration and EEG effect was successfully described by the sigmoidal Emax pharmacodynamic model. Between opioids significant differences in potency (EC50 range 1.2-451 ng/ml) and intrinsic activity (alpha range 18-109 microV) were observed. A statistically significant correlation was observed between the values of the in vivo k1e and the apparent passive permeability as determined in vitro in MDCK:MDR1 monolayers. It can be concluded that unlike other opioids, only morphine displays complex biophase distribution kinetics, which can be explained by its relatively low passive permeability and the interaction with active transporters at the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18467078     DOI: 10.1016/j.ejps.2008.03.003

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  10 in total

1.  Population PK/PD analysis of metformin using the signal transduction model.

Authors:  Jung-woo Chae; In-hwan Baek; Byung-yo Lee; Seong-kwon Cho; Kwang-il Kwon
Journal:  Br J Clin Pharmacol       Date:  2012-11       Impact factor: 4.335

2.  Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.

Authors:  E D Kharasch; A Francis; A London; K Frey; T Kim; J Blood
Journal:  Clin Pharmacol Ther       Date:  2011-05-11       Impact factor: 6.875

3.  Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge tests.

Authors:  Zheng Guan; Linda E Klumpers; Olubukayo-Opeyemi Oyetayo; Jules Heuberger; Joop M A van Gerven; Jasper Stevens
Journal:  Br J Clin Pharmacol       Date:  2016-01-29       Impact factor: 4.335

Review 4.  Translational pain research: evaluating analgesic effect in experimental visceral pain models.

Authors:  Anne Estrup Olesen; Trine Andresen; Lona Louring Christrup; Richard N Upton
Journal:  World J Gastroenterol       Date:  2009-01-14       Impact factor: 5.742

Review 5.  Electroencephalogram-based pharmacodynamic measures: a review.

Authors:  Michael Bewernitz; Hartmut Derendorf
Journal:  Int J Clin Pharmacol Ther       Date:  2012-03       Impact factor: 1.366

6.  Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.

Authors:  Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-30       Impact factor: 2.745

7.  The optimal effect-site concentration of sufentanil for laryngeal mask insertion during induction with target-controlled propofol infusion at 4.0 μg/mL.

Authors:  Roshdi R Al-Metwalli
Journal:  Saudi J Anaesth       Date:  2014-04

Review 8.  Opioids and the Blood-Brain Barrier: A Dynamic Interaction with Consequences on Drug Disposition in Brain.

Authors:  Catarina Chaves; Fernando Remiao; Salvatore Cisternino; Xavier Decleves
Journal:  Curr Neuropharmacol       Date:  2017-11-14       Impact factor: 7.363

9.  Electrocortical changes associating sedation and respiratory depression by the opioid analgesic fentanyl.

Authors:  Gaspard Montandon; Richard L Horner
Journal:  Sci Rep       Date:  2019-10-01       Impact factor: 4.379

Review 10.  Understanding the Blood-Brain Barrier and Beyond: Challenges and Opportunities for Novel CNS Therapeutics.

Authors:  Elizabeth C M de Lange; Margareta Hammarlund Udenaes
Journal:  Clin Pharmacol Ther       Date:  2022-02-27       Impact factor: 6.903

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.